ATE420078T1 - Pyrimidinonen als virale polymerase inhibitoren - Google Patents

Pyrimidinonen als virale polymerase inhibitoren

Info

Publication number
ATE420078T1
ATE420078T1 AT03700366T AT03700366T ATE420078T1 AT E420078 T1 ATE420078 T1 AT E420078T1 AT 03700366 T AT03700366 T AT 03700366T AT 03700366 T AT03700366 T AT 03700366T AT E420078 T1 ATE420078 T1 AT E420078T1
Authority
AT
Austria
Prior art keywords
sup
pyrimidinones
polymerase inhibitors
viral polymerase
inhibitors
Prior art date
Application number
AT03700366T
Other languages
German (de)
English (en)
Inventor
Salvatore Avolio
Stefania Colarusso
Immacolata Conte
Steven Harper
Uwe Koch
Savina Malancona
Victor Matassa
Frank Narjes
Alessia Petrocchi
Vincenzo Summa
Original Assignee
Angeletti P Ist Richerche Bio
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Angeletti P Ist Richerche Bio filed Critical Angeletti P Ist Richerche Bio
Application granted granted Critical
Publication of ATE420078T1 publication Critical patent/ATE420078T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52Two oxygen atoms
    • C07D239/54Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C07D239/545Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/557Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms, e.g. orotic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Saccharide Compounds (AREA)
AT03700366T 2002-01-18 2003-01-15 Pyrimidinonen als virale polymerase inhibitoren ATE420078T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0201179.9A GB0201179D0 (en) 2002-01-18 2002-01-18 Therapeutic agents

Publications (1)

Publication Number Publication Date
ATE420078T1 true ATE420078T1 (de) 2009-01-15

Family

ID=9929352

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03700366T ATE420078T1 (de) 2002-01-18 2003-01-15 Pyrimidinonen als virale polymerase inhibitoren

Country Status (8)

Country Link
US (1) US20050130997A1 (enExample)
EP (1) EP1470113B1 (enExample)
JP (1) JP4498745B2 (enExample)
AT (1) ATE420078T1 (enExample)
CA (1) CA2473508A1 (enExample)
DE (1) DE60325692D1 (enExample)
GB (1) GB0201179D0 (enExample)
WO (1) WO2003062211A1 (enExample)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004062613A2 (en) 2003-01-13 2004-07-29 Bristol-Myers Squibb Company Hiv integrase inhibitors
ATE478886T1 (de) 2003-07-25 2010-09-15 Idenix Pharmaceuticals Inc Purin nucleoside für die behandlung von durch flavividrae verursachten krankheiten, einschliesslich hepatitis c
WO2005016384A1 (ja) * 2003-08-13 2005-02-24 Bf Research Institute, Inc. アミロイド蓄積性疾患のプローブ、アミロイド染色剤、アミロイド蓄積性疾患の治療および予防薬、ならびに神経原線維変化の診断プローブおよび染色剤
AR046938A1 (es) * 2003-12-12 2006-01-04 Merck & Co Inc Procedimiento para preparar hexahidropirimido[1,2-a]azepin-2-carboxilatos y compuetos similares
IN2012DN04853A (enExample) 2004-02-20 2015-09-25 Boehringer Ingelheim Int
AU2006242475B2 (en) 2005-05-02 2011-07-07 Merck Sharp & Dohme Corp. HCV NS3 protease inhibitors
US7470664B2 (en) 2005-07-20 2008-12-30 Merck & Co., Inc. HCV NS3 protease inhibitors
JP4705984B2 (ja) 2005-08-01 2011-06-22 メルク・シャープ・エンド・ドーム・コーポレイション Hcvns3プロテアーゼ阻害剤としての大環状ペプチド
EP1937678B1 (en) * 2005-10-04 2011-07-27 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Hiv integrase inhibitors
GB0609492D0 (en) 2006-05-15 2006-06-21 Angeletti P Ist Richerche Bio Therapeutic agents
GB0612423D0 (en) 2006-06-23 2006-08-02 Angeletti P Ist Richerche Bio Therapeutic agents
AU2007309544B2 (en) 2006-10-24 2012-05-31 Msd Italia S.R.L. HCV NS3 protease inhibitors
EP2079480B1 (en) 2006-10-24 2013-06-05 Merck Sharp & Dohme Corp. Hcv ns3 protease inhibitors
AU2007309546A1 (en) 2006-10-24 2008-05-02 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. HCV NS3 protease inhibitors
AU2007318165B2 (en) 2006-10-27 2011-11-17 Msd Italia S.R.L. HCV NS3 protease inhibitors
EP2083844B1 (en) 2006-10-27 2013-11-27 Merck Sharp & Dohme Corp. Hcv ns3 protease inhibitors
EP2121707B1 (en) 2006-12-20 2012-12-05 Istituto di Ricerche di Biologia Molecolare P. Angeletti S.R.L. Antiviral indoles
GB0625345D0 (en) 2006-12-20 2007-01-31 Angeletti P Ist Richerche Bio Therapeutic compounds
GB0625349D0 (en) 2006-12-20 2007-01-31 Angeletti P Ist Richerche Bio Therapeutic compounds
EP2494991A1 (en) 2007-05-04 2012-09-05 Vertex Pharmaceuticals Incorporated Combination therapy for the treatment of HCV infection
US7763630B2 (en) 2007-06-06 2010-07-27 Bristol-Myers Squibb Company HIV integrase inhibitors
CN101801982A (zh) 2007-07-17 2010-08-11 P.安杰莱蒂分子生物学研究所 用于治疗丙型肝炎感染的大环吲哚衍生物
US8927569B2 (en) 2007-07-19 2015-01-06 Merck Sharp & Dohme Corp. Macrocyclic compounds as antiviral agents
EP2188274A4 (en) * 2007-08-03 2011-05-25 Boehringer Ingelheim Int VIRAL POLYMERASE HEMMER
EA201000948A1 (ru) 2007-12-19 2011-02-28 Бёрингер Ингельхайм Интернациональ Гмбх Ингибиторы вирусной полимеразы
EP2271345B1 (en) 2008-04-28 2015-05-20 Merck Sharp & Dohme Corp. Hcv ns3 protease inhibitors
EP2540349B1 (en) 2008-07-22 2014-02-12 Merck Sharp & Dohme Corp. Pharmaceutical compositions comprising a macrocyclic quinoxaline compound which is an hcv ns3 protease inhibitor
MX2011007195A (es) 2009-01-07 2013-07-12 Scynexis Inc Derivado de ciclosporina para el uso en el tratamiento de infección de virus de hepatitis c (vhc) y virus de inmunodeficiencia humana (vih).
SG173584A1 (en) 2009-02-06 2011-09-29 Elan Pharm Inc Inhibitors of jun n-terminal kinase
US8143244B2 (en) 2009-02-26 2012-03-27 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
WO2010111437A1 (en) * 2009-03-25 2010-09-30 Abbott Laboratories Antiviral compounds and uses thereof
US8828930B2 (en) 2009-07-30 2014-09-09 Merck Sharp & Dohme Corp. Hepatitis C virus NS3 protease inhibitors
US8383639B2 (en) 2009-10-15 2013-02-26 Bristol-Myers Squibb Company HIV integrase inhibitors
KR101382730B1 (ko) * 2010-08-13 2014-04-08 에프. 호프만-라 로슈 아게 헤테로환형 항바이러스성 화합물
WO2012151567A1 (en) * 2011-05-05 2012-11-08 St. Jude Children's Research Hospital Pyrimidinone compounds and methods for preventing and treating influenza

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2260319B (en) * 1991-10-07 1995-12-06 Norsk Hydro As Acyl derivatives of nucleosides and nucleoside analogues having anti-viral activity
DE19817265A1 (de) * 1998-04-18 1999-10-21 Bayer Ag Verwendung von Dihydropyrimidinen als Arzneimittel und neue Stoffe
CN1324250A (zh) * 1998-09-04 2001-11-28 维洛药品公司 治疗或预防病毒感染及其所致疾病的方法
GB0017676D0 (en) * 2000-07-19 2000-09-06 Angeletti P Ist Richerche Bio Inhibitors of viral polymerase

Also Published As

Publication number Publication date
JP4498745B2 (ja) 2010-07-07
DE60325692D1 (de) 2009-02-26
EP1470113A1 (en) 2004-10-27
JP2005524627A (ja) 2005-08-18
US20050130997A1 (en) 2005-06-16
CA2473508A1 (en) 2003-07-31
WO2003062211A1 (en) 2003-07-31
EP1470113B1 (en) 2009-01-07
GB0201179D0 (en) 2002-03-06

Similar Documents

Publication Publication Date Title
ATE420078T1 (de) Pyrimidinonen als virale polymerase inhibitoren
GB0017676D0 (en) Inhibitors of viral polymerase
CY1112108T1 (el) Αναστολεις ιου ηπατιτιδας c
PT1654261E (pt) Compostos inibidores da hepatite c
EA200700038A1 (ru) Ингибиторы вирусных полимераз
WO2005054430A3 (en) Hepatitis c virus inhibitors
IS8448A (is) Lifrarbólgu C-veirutálmar
NZ514403A (en) Fused-ring compounds and use thereof as drugs
GT200200117A (es) Derivados de nucleosidos
WO2002048116A3 (en) Inhibitors of hepatitis c virus ns3 protease
ATE474827T1 (de) Hcv-replikationshemmer
WO2002069903A3 (en) Nucleosides, preparation thereof and use as inhibitors of rna viral polymerases
ATE245641T1 (de) Antivirale pyrimidinderivate
TW200745035A (en) Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
DE69925918D1 (de) Diketosäure-derivate als hemmstoffe von polymerasen
DE602004029866D1 (de) Peptidanaloga mit inhibitorischer wirkung auf hepatitis c
TW200615275A (en) Hepatitis C inhibitor dipeptide analogs
TW200745120A (en) Indolobenzazepine HCV NS5B inhibitors
UA86962C2 (en) Viral polymerase inhibitors
WO2006027628A3 (en) Naphthalimide derivatives as antiviral agents
MA32006B1 (fr) Inhibiteurs de polymerase virale
DK1280813T3 (da) Antivirale pyrimidin-nukleosidanaloger
WO2005084192A3 (en) Novel 2’-c-methyl nucleoside derivatives
AU2003224371A1 (en) Inhibitors of hepatitis c virus rna-dependent rna polymerase, and compositions and treatments using the same
EA200600046A1 (ru) Производные 6-[2-(фосфонометокси)алкокси]пиримидинов (варианты), способ их получения (варианты), фармацевтическая композиция на их основе и способ лечения вирусной инфекции

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties